External validity of type 2 diabetes clinical trials on cardiovascular outcomes for a multimorbid population

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade de São Paulo (USP)-
Autor(es): dc.contributorUniversidade Estadual Paulista (Unesp)-
Autor(es): dc.creatorLazar Neto, Felippe-
Autor(es): dc.creatorMendes, Thiago Bosco [UNESP]-
Autor(es): dc.creatorMatos, Paulo Marcelo Pontes Gomes-
Autor(es): dc.creatorde Oliveira, Julio César-
Autor(es): dc.creatorFavarato, Maria Helena Sampaio-
Autor(es): dc.creatorLin, Chin An-
Autor(es): dc.creatorMartins, Milton Arruda-
Data de aceite: dc.date.accessioned2022-02-22T00:45:09Z-
Data de disponibilização: dc.date.available2022-02-22T00:45:09Z-
Data de envio: dc.date.issued2021-06-25-
Data de envio: dc.date.issued2021-06-25-
Data de envio: dc.date.issued2021-04-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1111/dom.14303-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/205735-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/205735-
Descrição: dc.descriptionAim: To investigate the external validity of recent antihyperglycaemic trials evaluating cardiovascular outcomes in a multimorbid population. Materials and Methods: Selection criteria of 15 randomized controlled trials from the 2020 American Diabetes Association Standard of Care statement were applied in a stepwise manner to tertiary care patients with type 2 diabetes. Primary outcomes were the number of patients eligible per individual trial and for the aggregate of trials. Secondary outcomes included patient predictors of trial eligibility. Results: Of 1059 patients, the mean (SD) age was 66 (10.74) years, the median (IQR) Charlson index was 2 (2, 3) and 458 (43%) had documented cardiovascular disease. The median (IQR) number of patients included in individual trials was 263 (174.25–308.75) and 795 (75.1%) of them were eligible for at least one trial. Among those 264 ineligible, 127 (48.1%) had an HbA1c level of 7% or less and no cardiovascular disease; 53.5% and 34.4% of the patients were eligible for two and three different classes of drugs, respectively. The strongest predictor of trial eligibility was cardiovascular disease (risk ratio 2.17, 95% CI 2.01–2.35). Conclusions: A considerable proportion of multimorbid patients would be eligible for recent antihyperglycaemic trials. This positive finding can be attributed to development guidance in diabetes trials and the different approach we took, in which we evaluated inclusion by trials as an aggregate.-
Descrição: dc.descriptionDepartment of Internal Medicin Faculdade de Medicina da Universidade de São Paulo (FMUSP)-
Descrição: dc.descriptionDepartment of Internal Medicine Faculdade de Medicina da Universidade Estadual de São Paulo (UNESP)-
Descrição: dc.descriptionDepartment of Internal Medicine Faculdade de Medicina da Universidade Estadual de São Paulo (UNESP)-
Formato: dc.format971-979-
Idioma: dc.languageen-
Relação: dc.relationDiabetes, Obesity and Metabolism-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectantidiabetic drug-
Palavras-chave: dc.subjectcanagliflozin-
Palavras-chave: dc.subjectcardiovascular disease-
Palavras-chave: dc.subjectDPP-4 inhibitor-
Palavras-chave: dc.subjectGLP-1-
Palavras-chave: dc.subjectinsulin analogues-
Título: dc.titleExternal validity of type 2 diabetes clinical trials on cardiovascular outcomes for a multimorbid population-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.